Increased expression of herpesvirus entry mediator in 1,25‑dihydroxyvitamin D3‑treated mouse bone marrow‑derived dendritic cells promotes the generation of CD4+CD25+Foxp3+ regulatory T cells

Huang,Yi; Zhao,Yan; Ran,Xuemei; Wang,Changzheng

doi:10.3892/mmr.2013.1874

Increased expression of herpesvirus entry mediator in 1,25‑dihydroxyvitamin D3‑treated mouse bone marrow‑derived dendritic cells promotes the generation of CD4+CD25+Foxp3+ regulatory T cells

Authors:
- Yi Huang
- Yan Zhao
- Xuemei Ran
- Changzheng Wang
View Affiliations

Affiliations: Institute of Respiratory Diseases, Xinqiao Hospital, The Third Military Medical University, Chongqing 430037, P.R. China, Department of Respiratory Medicine, Second Affiliated Hospital, Chongqing Medical University, Chongqing 404000, P.R. China
Published online on: December 18, 2013 https://doi.org/10.3892/mmr.2013.1874
Pages: 813-818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cells (DCs) can initiate immune responses or induce immune tolerance. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is a secosteroid hormone that can induce tolerogenic dendritic cells favoring the induction of regulatory T cells (Treg). The present study revealed a tolerogenic effect of 1,25(OH)2D3 on the phenotype and function of ovalbumin (OVA)‑activated mouse bone marrow‑derived DCs. Three inhibitory molecules associated with tolerogenic DCs, programmed death‑ligand-1 (PD‑L1), PD‑L2 and herpesvirus entry mediator (HVEM) and the expression of co‑stimulatory molecules (CD80, CD86 and CD40) on 1,25(OH)2D3‑treated DCs were examined. The levels of interleukin (IL)‑2, IL‑6 and IL‑10 secreted by 1,25(OH)2D3‑treated DCs were analyzed. The capability of 1,25(OH)2D3‑treated DCs to induce CD4+CD25+Foxp3+ Treg and the stimulation of allogeneic CD4+ T‑cell proliferation in mixed lymphocyte reaction (MLR) was studied. 1,25(OH)2D3‑treated DCs induced up to 21.0‑fold upregulation of the HVEM expression and 4.1‑fold enhancement of the HVEM expression upon activation with OVA [OVA‑D3/immature (im)DCs]. PD‑L1 was not affected by 1,25(OH)2D3‑treated DCs and downregulated PD‑L2 expression on 1,25(OH)2D3‑treated DCs and OVA‑D3/imDC. The expression of co‑stimulatory molecules (CD80, CD86 and CD40) was downregulated in 1,25(OH)2D3‑treated DCs and OVA‑D3/imDC. Furthermore, 1,25(OH)2D3‑treated DCs secreted much higher levels of IL‑10, however lower levels of IL‑2 and IL‑6 compared with the activated control DCs. Together with this pattern of cytokines, 1,25(OH)2D3‑treated DCs exhibited low allogeneic CD4+ T‑cell stimulatory activity and a higher number of CD4+CD25+Foxp3+ cells in the MLR cultures but not in the activated control DCs. These findings indicate that 1,25(OH)2D3 possesses the immunosuppressive properties by upregulating the expression of the inhibitory molecules, HVEM, which may be therapeutically useful in controlling chronic immune and/or inflammatory diseases.

View Figures

View References

1	Casteels K, Bouillon R, Waer M and Mathieu C: Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Curr Opin Nephrol Hypertens. 4:313–318. 1995. View Article : Google Scholar : PubMed/NCBI
2	Carlberg C: Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 164:29–42. 2003. View Article : Google Scholar : PubMed/NCBI
3	Griffin MD, Xing N and Kumar R: Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr. 23:117–145. 2003. View Article : Google Scholar : PubMed/NCBI
4	Mathieu C and Adorini L: The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med. 8:174–179. 2002. View Article : Google Scholar : PubMed/NCBI
5	Adorini L: Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol. 2:1017–1028. 2002. View Article : Google Scholar : PubMed/NCBI
6	Adorini L: 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr Opin Investig Drugs. 3:1458–1463. 2002.PubMed/NCBI
7	Deluca HF and Cantorna MT: Vitamin D: its role and uses in immunology. FASEB J. 15:2579–2585. 2001. View Article : Google Scholar : PubMed/NCBI
8	Penna G and Adorini L: 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 164:2405–2411. 2000. View Article : Google Scholar
9	Piemonti L, Monti P, Sironi M, et al: Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol. 164:4443–4451. 2000. View Article : Google Scholar : PubMed/NCBI
10	Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ and Kumar R: Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 270:701–708. 2000. View Article : Google Scholar : PubMed/NCBI
11	van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO and Mathieu C: Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes. 51:2119–2125. 2002.PubMed/NCBI
12	Gauzzi MC, Purificato C, Donato K, et al: Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol. 174:270–276. 2005. View Article : Google Scholar : PubMed/NCBI
13	Dai H, Zhu H, Lei P, et al: Programmed death-1 signaling is essential for the skin allograft protection by alternatively activated dendritic cell infusion in mice. Transplantation. 88:864–873. 2009. View Article : Google Scholar : PubMed/NCBI
14	Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH and Noelle RJ: Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci USA. 105:9331–9336. 2008.PubMed/NCBI
15	Chen C, Qu QX, Huang JA, et al: Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunobiology. 212:159–165. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kwon BS, Tan KB, Ni J, et al: A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 272:14272–14276. 1997. View Article : Google Scholar : PubMed/NCBI
17	Morel Y, Schiano de Colella JM, Harrop J, et al: Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol. 165:4397–4404. 2000. View Article : Google Scholar
18	Jung HW, La SJ, Kim JY, et al: High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases. Exp Mol Med. 35:501–508. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Subudhi SK, Anders RA, et al: The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest. 115:711–717. 2005. View Article : Google Scholar : PubMed/NCBI
20	Sedy JR, Gavrieli M, Potter KG, et al: B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 6:90–98. 2005. View Article : Google Scholar : PubMed/NCBI
21	Cai G, Wang H, Qin Q, et al: Amelioration of myocarditis by HVEM-overexpressing dendritic cells through induction of IL-10-producing cells. Cardiovasc Res. 84:425–433. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhang M, Tang H, Guo Z, et al: Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol. 5:1124–1133. 2004. View Article : Google Scholar : PubMed/NCBI
23	Latchman Y, Wood CR, Chernova T, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2:261–268. 2001. View Article : Google Scholar : PubMed/NCBI
24	Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kaliński P, Hilkens CM, Wierenga EA and Kapsenberg ML: T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunology Today. 20:561–567. 1999.PubMed/NCBI
26	Lutz MB and Schuler G: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23:445–449. 2002. View Article : Google Scholar : PubMed/NCBI
27	Anderson AE, Swan DJ, Sayers BL, et al: LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol. 85:243–250. 2009. View Article : Google Scholar : PubMed/NCBI
28	Alroy I, Towers TL and Freedman LP: Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 15:5789–5799. 1995.PubMed/NCBI
29	Wölfle SJ, Strebovsky J, Bartz H, et al: PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol. 41:413–424. 2011.PubMed/NCBI
30	Unger WW, Laban S, Kleijwegt FS, van der Slik AR and Roep BO: Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol. 39:3147–3159. 2009. View Article : Google Scholar : PubMed/NCBI
31	Kuipers H, Muskens F, Willart M, et al: Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4⁺ T cell activation. Eur J Immunol. 36:2472–2482. 2006. View Article : Google Scholar : PubMed/NCBI
32	Sadeghi K, Wessner B, Laggner U, et al: Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 36:361–370. 2006. View Article : Google Scholar : PubMed/NCBI
33	Hewison M, Freeman L, Hughes SV, et al: Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 170:5382–5390. 2003. View Article : Google Scholar : PubMed/NCBI
34	Dong X, Craig T, Xing N, et al: Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J Biol Chem. 278:49378–49385. 2003. View Article : Google Scholar : PubMed/NCBI
35	Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ and Kumar R: Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA. 98:6800–6805. 2001. View Article : Google Scholar : PubMed/NCBI
36	Szeles L, Keresztes G, Töröcsik D, et al: 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol. 182:2074–2083. 2009. View Article : Google Scholar : PubMed/NCBI